BioExecutive International

BioExecutive International is dedicated to addressing the business and technology challenges facing biopharmaceutical executives. Every issue smartly covers concept to commercialization, offering business strategies, tools and perspectives to improve business skills, execute effective business plans and become better strategic business managers, partners, developers and marketers.

For more information please visit www.bioexecutiveintl.com.

back to top

De Facto Communications

De Facto Communications is one of Europe's most successful public relations consultancies in life science, healthcare, medical education and clinical trials marketing. Headquartered in London, De Facto is part of the Bell Pottinger Group and delivers award-winning, integrated communications programmes based on effective strategy, original thinking and attention-grabbing creativity.

www.defacto.com

back to top

The Journal of Biolaw & Business

Grow your business with The Journal of BioLaw & Business! The Journal of BioLaw & Business is the leading international publication established in 1997 to address emerging legal, business, scientific and regulatory issues impacting the growth of the biotechnology, life science and investment sectors. BioLaw's world-class expert advisory board, educational supporters and authors provide original substantive analyses, and valuable practical tools and guidance to biotechnology and life science executives, attorneys, biomedical researches, entrepreneurs, licensing and tech transfer specialists, investors and policy-makers. Special thematic BioLaw & Business Supplements (on topics such as licensing, intellectual property, bioinformatics, and venture financing) can also be ordered separately. On-line full text access is available to subscribers and member sites.

Published quarterly, with topic-specific supplements and electronic updates, BioLaw offers timely reporting,thoughtful analysis, case studies and practical solutions to present issues and future concerns in these emerging fields. It is designed for those who want to stay ahead of rapidly changing innovations. BioLaw's distinguished advisors and authors offer "real world" perspectives and the practical tools necessary to meet the sectors' unique challenges. For more information, contact: Robin JR Blatt, Publisher (editor@biolawbusiness.com)

www.biolawbusiness.com

Back to top

LaVoie Strategic Communications Group, Inc.

LaVoie Strategic Communications Group, Inc. (LaVoie Group) provides corporate communications, public relations and investor relations counsel and execution to private and publicly-held life science and healthcare clients. Our clients range from start-ups to industry leaders. We help our clients communicate value to their key constituencies.

www.lavoiegroup.com

Back to top

Private Equity Insider

Plug In to Industry Secrets

Back to top

Richard Lewis Communications

Richard Lewis Communications, Inc. offers full service corporate and investor communications to therapeutically focused biotechnology companies in all stages of development.

Through our team of senior level counselors, we offer a deep understanding of our clients' business strategies. We specialize in designing programs related to strategic planning, investor relations, public and media relations, business development, patient advocacy outreach, and clinical trials recruitment strategies and execution.

Our strengths are combining our "hands-on" knowledge of drug development with concrete biotechnology and Wall Street experience - both on the client side and agency side. This unique combination enables us to provide our clients with more than 40 years of combined experience to develop a tactical communications program that addresses the unique needs of both private and public biotechnology companies seeking to increase their operational effectiveness.

For more information about RLC, visit www.rlcinc.com or call Gregory Tiberend, EVP & COO, at 212-827-0020.

Back to top

GSAS Harvard Biotechnology Club

In the five years since the GSAS Harvard Biotechnology Club was founded by three former Harvard graduate students, the Club has grown to include over 2500 academic members and 1800 member from industry, including members from around the world. A central fixture in the Boston biotech community, the Biotech Club constantly strives to bridge the gap between industry, academia, and the general public on matters relating to biotechnology and its applications. The Club’s web-content and seminars cover the many facets of the biotechnology and pharmaceutical industry, as well as providing career assistance to its members. Many of the Club’s sponsors include top local biotech and pharmaceutical research firms, numerous intellectual property law and venture financing firms. The Club’s mission is to explore and raise awareness on every aspect of biotechnology.

www.thebiotechclub.org

Back to top